Summary

Location
at San Francisco, California and other locations
Dates
study started

Description

Summary

Expanded access for patients with cancer with RET activation who are ineligible for an ongoing selpercatinib (also known as LOXO-292) clinical trial or have other considerations that prevent access to selpercatinib through an existing clinical trial.

Details

N/A for expanded access

Keywords

Non Small Cell Lung Cancer Medullary Thyroid Cancer Colon Cancer Breast Cancer Pancreatic Cancer Papillary Thyroid Cancer Other Solid Tumors With Evidence of Activating RET Alteration Thyroid Neoplasms Thyroid Cancer, Papillary Thyroid Diseases Selpercatinib

Eligibility

You can join if…

  • Diagnosis of cancer with RET activation, who are not eligible for an ongoing selpercatinib clinical trial and are medically suitable for treatment with selpercatinib

You CAN'T join if...

  • Currently enrolled in an ongoing clinical study of selpercatinib or another RET inhibitor

Locations

  • UCSF Helen Diller Family Comprehensive Cancer Center not accepting new patients
    San Francisco California 94158 United States
  • Kaiser Permanente Medical Center not accepting new patients
    Vallejo California 94589 United States

Details

Status
not accepting new patients
Start Date
Sponsor
Loxo Oncology, Inc.
ID
NCT03906331
Study Type
Expanded Access
Last Updated